DK3135656T3 - Deutererede 1-piperazino-3-phenyl-indaner til behandling af skizofreni - Google Patents

Deutererede 1-piperazino-3-phenyl-indaner til behandling af skizofreni Download PDF

Info

Publication number
DK3135656T3
DK3135656T3 DK16179882.2T DK16179882T DK3135656T3 DK 3135656 T3 DK3135656 T3 DK 3135656T3 DK 16179882 T DK16179882 T DK 16179882T DK 3135656 T3 DK3135656 T3 DK 3135656T3
Authority
DK
Denmark
Prior art keywords
compound
deuterium
phenyl
chloro
treatment
Prior art date
Application number
DK16179882.2T
Other languages
English (en)
Inventor
Klaus Gjervig Jensen
Mikkel Fog Jacobsen
Peter Høngaard Andersen
Lassina Badolo
Mette Graulund Hvenegaard
Morten Jørgensen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Application granted granted Critical
Publication of DK3135656T3 publication Critical patent/DK3135656T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Claims (22)

1. Forbindelse af formlen Y:
hvor, R1 - R10 uafhængigt er hydrogen eller deuterium, hvor R6-R10 hver er deuterium eller et farmaceutisk acceptabelt syreadditionssalt deraf til anvendelse som et medikament.
2. Forbindelse ifølge krav 1 til anvendelse som et medikament, hvor R3-R4 5 hver er hydrogen.
3. Forbindelse ifølge krav 1 til anvendelse som et medikament, hvor R3-R5 hver er deuterium.
4. Forbindelse ifølge et hvilket som helst af kravene 1 og 2 til anvendelse som et medikament, hvor forbindelsen er
5. Forbindelse ifølge et hvilket som helst af kravene 1 og 2 til anvendelse som et medikament, hvor forbindelsen er
6. Forbindelse ifølge et hvilket som helst af kravene 1 og 3 til anvendelse som et medikament, hvor forbindelsen er
7. Forbindelse ifølge et hvilket som helst af kravene 1 og 3 til anvendelse som et medikament, hvor forbindelsen er
8. Forbindelse ifølge et hvilket som helst af kravene 1 og 6 til anvendelse som et medikament, hvor forbindelsen er hydrogentartratsaltet af
9. Forbindelse ifølge krav 8 til anvendelse som et medikament, hvor forbindelsen eksisterer i polymorf form, med et XRPD diffraktionsmønster som anført i Figur 18.
10. Forbindelse ifølge et hvilket som helst af kravene 1 til 9 til anvendelse som et medikament, hvor forbindelsen anvendes som et medikament i kombination med et eller flere neuroleptiske midler.
11. Forbindelse ifølge et hvilket som helst af kravene 1 til 10 til anvendelse som et medikament, hvor forbindelsen anvendes som et medikament i kombination med et eller flere neuroleptiske midler, hvor det ene eller flere af de neuroleptiske
milder er valgt fra gruppen bestående af sertindol, olanzapin, risperidon, quetiapin, aripiprazol, haloperidol, clozapin, ziprasidon og osanetant.
12. Forbindelse af formlen Y:
hvor, R1 - R10 uafhængigt er hydrogen eller deuterium, hvor R6-R10 hver er deuterium eller et farmaceutisk acceptabelt syreadditionssalt deraf til anvendelse i behandlingen af skizofreni.
13. Forbindelse ifølge krav 12 til anvendelse i behandlingen af skizofreni, hvor R3-R5 hver er hydrogen.
14. Forbindelse ifølge krav 12 til anvendelse i behandlingen af skizofreni, hvor R3-R5 hver er deuterium.
15. Forbindelse ifølge et hvilket som helst af kravene 12 og 13 til anvendelse i behandlingen af skizofreni, hvor forbindelsen er
16. Forbindelse ifølge et hvilket som helst af kravene 12 og 13 til anvendelse i behandlingen af skizofreni, hvor forbindelsen er
17. Forbindelse ifølge et hvilket som helst af kravene 12 og 14 til anvendelse i behandlingen af skizofreni, hvor forbindelsen er
18. Forbindelse ifølge et hvilket som helst af kravene 12 og 14 til anvendelse i behandlingen af skizofreni, hvor forbindelsen er
19. Forbindelse ifølge et hvilket som helst af kravene 12 og 17 til anvendelse i behandlingen af skizofreni, hvor forbindelsen er hydrogentartratsaltet af
20. Forbindelse ifølge krav 19 til anvendelse i behandlingen af skizofreni, hvor forbindelsen eksisterer i polymorf form, med et XRPD diffraktionsmønster som anført i Figur 18.
21. Forbindelse ifølge et hvilket som helst af kravene 12 til 20 til anvendelse i behandlingen af skizofreni, hvor forbindelsen anvendes i behandlingen af skizofreni i kombination med et eller flere neuroleptiske midler.
22. Forbindelse ifølge et hvilket som helst af kravene 12 til 20 til anvendelse i behandlingen af skizofreni, hvor forbindelsen anvendes i behandlingen af skizofreni i kombination med et eller flere neuroleptiske midler, hvor det ene eller
flere af de neuroleptiske midler er valgt fra gruppen bestående af sertindol, olanzapin, risperidon, quetiapin, aripiprazol, haloperidol, clozapin, ziprasidon og osanetant.
DK16179882.2T 2011-06-20 2012-06-19 Deutererede 1-piperazino-3-phenyl-indaner til behandling af skizofreni DK3135656T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161498651P 2011-06-20 2011-06-20
US201161537103P 2011-09-21 2011-09-21
EP12748046.5A EP2720989B1 (en) 2011-06-20 2012-06-19 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia

Publications (1)

Publication Number Publication Date
DK3135656T3 true DK3135656T3 (da) 2019-04-23

Family

ID=46682855

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12748046.5T DK2720989T3 (da) 2011-06-20 2012-06-19 Deutererede 1-piperazino-3-phenyl-indaner til behandling af skizofreni
DK16179882.2T DK3135656T3 (da) 2011-06-20 2012-06-19 Deutererede 1-piperazino-3-phenyl-indaner til behandling af skizofreni

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12748046.5T DK2720989T3 (da) 2011-06-20 2012-06-19 Deutererede 1-piperazino-3-phenyl-indaner til behandling af skizofreni

Country Status (40)

Country Link
US (8) US8575174B2 (da)
EP (4) EP2720989B1 (da)
JP (1) JP5668177B2 (da)
KR (2) KR101939546B1 (da)
CN (1) CN103649019B (da)
AP (1) AP3310A (da)
AR (1) AR086987A1 (da)
AU (1) AU2012273657B2 (da)
BR (1) BR112013031702B1 (da)
CA (1) CA2837820C (da)
CL (1) CL2013003646A1 (da)
CO (1) CO6821965A2 (da)
CR (1) CR20130654A (da)
CY (2) CY1118158T1 (da)
DK (2) DK2720989T3 (da)
DO (1) DOP2013000305A (da)
EA (1) EA024651B1 (da)
EC (1) ECSP14013155A (da)
ES (3) ES2939477T3 (da)
GE (1) GEP201706655B (da)
GT (1) GT201300304A (da)
HK (1) HK1197228A1 (da)
HR (2) HRP20161348T1 (da)
HU (2) HUE044043T2 (da)
IL (1) IL229640B (da)
JO (1) JO3128B1 (da)
LT (2) LT3135656T (da)
MA (1) MA35268B1 (da)
MD (1) MD4538C1 (da)
ME (2) ME02513B (da)
MX (1) MX339552B (da)
MY (1) MY196998A (da)
PE (2) PE20150928A1 (da)
PL (2) PL2720989T3 (da)
PT (2) PT2720989T (da)
RS (2) RS58546B1 (da)
SI (2) SI2720989T1 (da)
SM (1) SMT201600383B (da)
TW (3) TWI659741B (da)
WO (1) WO2012176066A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2720989T1 (sl) 2011-06-20 2016-11-30 H. Lundbeck A/S Devterirani 1-piperazino-3-fenil indani za zdravljenje shizofrenije
AR094054A1 (es) * 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma
KR102638176B1 (ko) 2017-09-07 2024-02-20 오츠카 세이야쿠 가부시키가이샤 중수소화-알킬을 사용하여 피페리딘 유도체 내의 피페리딘 질소를 모노-알킬화시키는 공업적 방법
US20210395208A1 (en) * 2018-10-29 2021-12-23 H. Lundeck A/S Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
CN113056457A (zh) 2018-12-03 2021-06-29 H.隆德贝克有限公司 4-((1R,3S)-6-氯-3-苯基-2,3-二氢-1H-茚-1-基)-1,2,2-三甲基哌嗪和4-((1R,3S)-6-氯-3-(苯基-d5)-2,3-二氢-1H-茚-1-基)-2,2-二甲基-1-(甲基-d3)哌嗪的前药
JP7548906B2 (ja) * 2018-12-21 2024-09-10 テラン バイオサイエンシズ インコーポレイテッド ボリナンセリンの重水素化形態および誘導体
CA3132953A1 (en) * 2019-03-13 2020-09-17 Otsuka Pharmaceutical Co., Ltd. Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE50867B1 (en) 1980-02-29 1986-08-06 Kefalas As Indane derivatives
GB8427125D0 (en) 1984-10-26 1984-12-05 Lundbeck & Co As H Organic compounds
DE3581638D1 (de) 1984-12-04 1991-03-07 Sandoz Ag Inden-analoga von mevalonolakton und ihre derivate.
DK286990D0 (da) 1990-12-04 1990-12-04 Lundbeck & Co As H Indanderivater
DK55192D0 (da) 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1087725C (zh) * 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
WO1999015524A1 (en) 1997-09-23 1999-04-01 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
SE9904850D0 (sv) 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
TWI403505B (zh) * 2003-08-18 2013-08-01 Lundbeck & Co As H 反－４－（（１ｒ，３ｓ）－６－氯－３－苯基二氫茚－１－基）－１，２，２－三甲基哌之琥珀酸鹽和丙二酸鹽及其作為藥物之用途
AU2004265021B2 (en) 2003-08-18 2010-05-27 H. Lundbeck A/S Succinate and malonate salt of trans-4-(IR,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
WO2005121088A1 (en) 2004-06-08 2005-12-22 A. Carlsson Research Ab New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
RU2366654C2 (ru) 2004-06-08 2009-09-10 ЭнЭсЭйБи, ФИЛИАЛ АФ НЕУРОСЕРЧ СВИДЕН АБ, СВЕРИЙЕ Новые дизамещенные фенилпиперидины/пиперазины в качестве модуляторов допаминовой нейротрансмиссии
MX2007009816A (es) 2005-02-16 2007-09-07 Lundbeck & Co As H Sales de tartrato y de malato de trans-1-((1r,3s)-6-cloro-3- fenilindan-1-i1)-3,3-dimetilpiperazina.
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
US7863274B2 (en) 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
CA2616383C (en) 2005-07-29 2015-06-09 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
KR101068180B1 (ko) 2005-12-01 2011-09-28 오스펙스 파마슈티칼스, 인코포레이티드 세로토닌성 및/또는 노르에피네프린성 활성을 갖는 치환된펜에틸아민
JP4986462B2 (ja) 2006-01-27 2012-07-25 シャープ株式会社 太陽電池ストリングおよびその製造方法、ならびに、その太陽電池ストリングを用いる太陽電池モジュール
TW200819426A (en) 2006-08-31 2008-05-01 Lundbeck & Co As H Novel indane compounds
WO2008086158A1 (en) 2007-01-04 2008-07-17 Smithkline Beecham Corporation Benzodihydroquinazoline as pi3 kinase inhibitors
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
KR20100105802A (ko) 2007-04-19 2010-09-29 콘서트 파마슈티컬즈, 인크. 중수소화된 모르폴리닐 화합물
EP1997479A1 (en) 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration
WO2008156632A1 (en) 2007-06-12 2008-12-24 Concert Pharmaceuticals, Inc. Azapeptide derivatives
US20090062303A1 (en) 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched ziprasidone
KR20110021754A (ko) 2008-05-07 2011-03-04 하. 룬드벡 아크티에셀스카브 인지 결함 치료 방법
CA2732613A1 (en) 2008-10-03 2010-04-08 H. Lundbeck A/S Oral formulation
US8778401B2 (en) 2008-10-28 2014-07-15 Agency For Science, Technology And Research Mesoporous material excipients for poorly aqueous soluble ingredients
EP2362865A2 (en) 2008-10-28 2011-09-07 Concert Pharmaceuticals Inc. Deuterated 2-propylpentanoic acid compounds
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
TW201102370A (en) 2009-07-07 2011-01-16 Lundbeck & Co As H Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl piperazine
US8557994B2 (en) 2009-07-27 2013-10-15 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
US8658236B2 (en) * 2009-08-21 2014-02-25 Deuteria Beverages, Llc Alcoholic compositions having a lowered risk of acetaldehydemia
KR101149529B1 (ko) 2009-09-11 2012-05-25 한국화학연구원 인덴온 유도체 및 이를 포함하는 약학적 조성물
CN102020522A (zh) * 2009-09-21 2011-04-20 陈松源 氘代药物的制备方法和应用
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
WO2011059080A1 (ja) * 2009-11-16 2011-05-19 第一三共株式会社 同位体置換されたジアミン誘導体
ES2647361T3 (es) 2010-01-07 2017-12-21 Alkermes Pharma Ireland Limited Profármacos de sales de amonio cuaternario
CN104496780A (zh) 2010-11-09 2015-04-08 株式会社钟化 卤化茚酮类及使用其的光学活性茚满酮类或光学活性茚满醇类的制造方法
CN103429577A (zh) 2011-01-07 2013-12-04 H.隆德贝克有限公司 4-((1r,3s)-6-氯-3-苯基-茚满-1-基)-1,2,2-三甲基哌嗪和1-((1r,3s)-6-氯-3-苯基-茚满-1-基)-3,3-二甲基哌嗪的拆分方法
WO2012137225A1 (en) 2011-04-08 2012-10-11 Sphaera Pharma Pvt. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
SI2720989T1 (sl) 2011-06-20 2016-11-30 H. Lundbeck A/S Devterirani 1-piperazino-3-fenil indani za zdravljenje shizofrenije
CA2886744A1 (en) 2012-10-04 2014-04-10 Inhibikase Therapeutics, Inc. Imatinib derivatives, their preparation and use to treat cancer and bacterial and viral infections
AR094054A1 (es) 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma

Also Published As

Publication number Publication date
AU2012273657B2 (en) 2016-07-21
US9216961B2 (en) 2015-12-22
EP3508468A1 (en) 2019-07-10
GEP201706655B (en) 2017-04-25
US11059798B2 (en) 2021-07-13
ECSP14013155A (es) 2014-02-28
US20160068497A1 (en) 2016-03-10
ES2939477T3 (es) 2023-04-24
CN103649019A (zh) 2014-03-19
BR112013031702A2 (pt) 2016-12-13
PL3135656T3 (pl) 2019-07-31
CY1121514T1 (el) 2020-05-29
SI3135656T1 (sl) 2019-05-31
CA2837820C (en) 2019-02-19
PE20141113A1 (es) 2014-09-25
KR20140041567A (ko) 2014-04-04
HUE030883T2 (en) 2017-06-28
ES2601213T3 (es) 2017-02-14
PL2720989T3 (pl) 2017-05-31
GT201300304A (es) 2015-01-16
SI2720989T1 (sl) 2016-11-30
AU2012273657A1 (en) 2013-12-12
CR20130654A (es) 2014-03-24
US9012453B2 (en) 2015-04-21
US20130281436A1 (en) 2013-10-24
US20200131143A1 (en) 2020-04-30
IL229640B (en) 2018-02-28
WO2012176066A1 (en) 2012-12-27
PT2720989T (pt) 2016-11-07
EA024651B1 (ru) 2016-10-31
KR101939546B1 (ko) 2019-01-16
EP4215512A1 (en) 2023-07-26
EP2720989B1 (en) 2016-08-10
RS58546B1 (sr) 2019-05-31
US20120322811A1 (en) 2012-12-20
HUE044043T2 (hu) 2019-09-30
KR101879474B1 (ko) 2018-07-17
US20220119362A1 (en) 2022-04-21
CA2837820A1 (en) 2012-12-27
LT3135656T (lt) 2019-04-25
CL2013003646A1 (es) 2014-07-04
ME03375B (me) 2020-01-20
MX339552B (es) 2016-05-31
US20190031631A1 (en) 2019-01-31
AR086987A1 (es) 2014-02-05
EP3135656A1 (en) 2017-03-01
US12116355B2 (en) 2024-10-15
CN103649019B (zh) 2015-09-16
EP2720989A1 (en) 2014-04-23
AP3310A (en) 2015-06-30
CY1118158T1 (el) 2017-06-28
MD4538C1 (ro) 2018-07-31
JP5668177B2 (ja) 2015-02-12
TWI659741B (zh) 2019-05-21
HK1197228A1 (zh) 2015-01-09
US8575174B2 (en) 2013-11-05
US10501427B2 (en) 2019-12-10
HRP20161348T1 (hr) 2016-12-02
US9617231B2 (en) 2017-04-11
MX2013014849A (es) 2014-03-31
PE20150928A1 (es) 2015-06-26
BR112013031702B1 (pt) 2021-11-03
MY196998A (en) 2023-05-17
EP3508468B1 (en) 2023-01-18
US20170158650A1 (en) 2017-06-08
DK2720989T3 (da) 2016-11-28
US20150307458A1 (en) 2015-10-29
HRP20190593T1 (hr) 2019-05-17
IL229640A0 (en) 2014-01-30
MD4538B1 (ro) 2017-12-31
PT3135656T (pt) 2019-05-03
MD20140004A2 (en) 2014-05-31
TWI627956B (zh) 2018-07-01
TW201902481A (zh) 2019-01-16
US10118907B2 (en) 2018-11-06
SMT201600383B (it) 2017-01-10
AP2013007338A0 (en) 2013-12-31
TW201722895A (zh) 2017-07-01
JP2014520140A (ja) 2014-08-21
ES2719145T3 (es) 2019-07-08
DOP2013000305A (es) 2014-02-28
ME02513B (me) 2017-02-20
MA35268B1 (fr) 2014-07-03
RS55304B1 (sr) 2017-03-31
EP3135656B1 (en) 2019-02-27
TWI614234B (zh) 2018-02-11
CO6821965A2 (es) 2013-12-31
KR20180075717A (ko) 2018-07-04
EA201490045A1 (ru) 2014-07-30
LT2720989T (lt) 2016-11-25
JO3128B1 (ar) 2017-09-20
NZ618222A (en) 2015-03-27
TW201311248A (zh) 2013-03-16

Similar Documents

Publication Publication Date Title
US12116355B2 (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
DK201500362A1 (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
OA16797A (en) Deuterated 1-Piperazino-3-Phenyl-Indanes for treatment of Schizophrenia.
NZ618222B2 (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia